UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1755-1762

2012

Volltextzugriff (PDF)

Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3687-3694

2008

Volltextzugriff (PDF)

Late Patient-Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase III Study

International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.1017-1024

2011

Volltextzugriff (PDF)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Oncotarget, 2016-07, Vol.7 (27), p.41948-41958

2016

Volltextzugriff (PDF)

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

BMC cancer, 2012-11, Vol.12 (1), p.534

2012

Volltextzugriff (PDF)

Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer

European journal of surgical oncology, 2005-09, Vol.31 (7), p.735-742

2005

Volltextzugriff (PDF)

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study

PloS one, 2014-02, Vol.9 (2), p.e87746

2014

Volltextzugriff (PDF)

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

International journal of cancer, 2015-11, Vol.137 (10), p.2470-2477

2015

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study

European journal of cancer (1990), 2012-04, Vol.48 (6), p.813-819

2012

Volltextzugriff (PDF)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer

Oncotarget, 2016-09, Vol.7 (37), p.59441-59457

2016

Volltextzugriff (PDF)

Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group

Acta oncologica, 2005, Vol.44 (8), p.904-912

2005

Volltextzugriff (PDF)

Quality of life during radiotherapy for rectal cancer

European journal of cancer (1990), 2003-03, Vol.39 (5), p.587-594

2003

Volltextzugriff (PDF)

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer

Annals of oncology, 2005-05, Vol.16 (suppl-1), p.i20-i21

2005

Volltextzugriff (PDF)

Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer

Journal of clinical oncology, 2004-01, Vol.22 (1), p.31-38

2004

Volltextzugriff (PDF)

Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer

JOURNAL OF CLINICAL ONCOLOGY, 2013, Vol.31 (15_suppl), p.3597-3597

2013

Volltextzugriff (PDF)

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

Annals of oncology, 2006-02, Vol.17 (2), p.252-258

2006

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Inhibition Induces Trichomegaly

Acta oncologica, 2003, Vol.42 (4), p.345-346

2003

Volltextzugriff (PDF)

Nationwide quality assurance of rectal cancer treatment

Colorectal disease, 2006-03, Vol.8 (3), p.224-229

2006

Volltextzugriff (PDF)

Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study

Radiotherapy and oncology, 2002-02, Vol.62 (2), p.207-213

2002

Volltextzugriff (PDF)

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer

Annals of oncology, 2003-07, Vol.14 (7), p.1006-1007

Tveit, K M

2003

Volltextzugriff (PDF)

Radiation therapy induced changes in male sex hormone levels in rectal cancer patients

Radiotherapy and oncology, 2003-09, Vol.68 (3), p.249-253

2003

Volltextzugriff (PDF)

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

Annals of oncology, 2002-12, Vol.13 (12), p.1868-1873

2002

Volltextzugriff (PDF)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

British journal of cancer, 2004-10, Vol.91 (8), p.1434-1441

2004

Volltextzugriff (PDF)

Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer

European journal of surgical oncology, 2001-11, Vol.27 (7), p.645-651

2001

Volltextzugriff (PDF)

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Acta oncologica, 2007, Vol.46 (7), p.982-988

2007

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(74)
Tagungsberichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(68)
Humans
(66)
Oncology
(55)
Female
(51)
Aged
(41)
Male
(41)
Middle Aged
(40)
Adult
(34)
Biological And Medical Sciences
(31)
Medical Sciences
(31)
Medicin Och Hälsovetenskap
(20)
Aged, 80 And Over
(18)
Tumors
(17)
Colorectal Neoplasms - Drug Therapy
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Rectal Neoplasms - Radiotherapy
(13)
Fluorouracil - Administration & Dosage
(12)
Surgery
(11)
Chemotherapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer

Late Patient-Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase III Study

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab

Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer

Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group

Quality of life during radiotherapy for rectal cancer

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer

Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer

Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil

Epidermal Growth Factor Receptor Inhibition Induces Trichomegaly

Nationwide quality assurance of rectal cancer treatment

Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer

Radiation therapy induced changes in male sex hormone levels in rectal cancer patients

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

Suchergebnisse filtern